Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Drug Metabolism And Disposition

• Publication date

  2011-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.110.035857PMID 21098644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?

  2009cited by this paper
• Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

  2009cited by this paper
• Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

  2008cited by this paper
• Estimation of Human Drug Clearance Using Multiexponential Techniques

  2008cited by this paper
• Challenges and opportunities with modelling and simulation in drug discovery and drug development

  2007cited by this paper
• Whole-body physiologically based pharmacokinetic models

  2007cited by this paper
• Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

  2007influential reference
• Rodgers T, Rowland M. 2006. Physiologically‐based Pharmacokinetic Modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257.

  2007cited by this paper
• Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

  2007cited by this paper
• An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

  2007cited by this paper
• Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs

  2007cited by this paper
• Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

  2007cited by this paper
• A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

  2006cited by this paper
• Prediction of metabolic drug clearance in humans: In vitro–in vivo extrapolation vs allometric scaling

  2006cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006cited by this paper
• ACCURACY OF ALLOMETRICALLY PREDICTED PHARMACOKINETIC PARAMETERS IN HUMANS: ROLE OF SPECIES SELECTION

  2005cited by this paper
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005cited by this paper
• Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.

  2005cited by this paper
• A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES

  2005influential reference
• Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination.

  2004cited by this paper
• Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.

  2004cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

  2004cited by this paper
• Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.

  2003cited by this paper
• Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution.

  2002cited by this paper
• Prediction of Clearance in Humans from In Vitro Human Liver Microsomes and Allometric Scaling. A Comparative Study of the Two Approaches

  2002cited by this paper
• Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

  2001cited by this paper
• Bioanalytical Method Validation—A Revisit with a Decade of Progress

  2000cited by this paper
• [Annual meeting of the American Association for Cancer Research].

  2000cited by this paper
• Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999influential reference
• Correlation of Plasma Clearance of 54 Extensively Metabolized Drugs Between Humans and Rats: Mean Allometric Coefficient of 0.66

  1998cited by this paper
• Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.

  1997cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997influential reference
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance.

  1996cited by this paper
• Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data.

  1995cited by this paper
• Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.

  1995cited by this paper
• Interspecies scaling and comparisons in drug development and toxicokinetics.

  1990cited by this paper
• Man versus beast: pharmacokinetic scaling in mammals.

  1986cited by this paper
• Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

  1984cited by this paper

• A hybrid framework of artificial intelligence-based neural network model (ANN) and central composite design (CCD) in quality by design formulation development of orodispersible moxifloxacin tablets: Physicochemical evaluation, compaction analysis, and its in-silico PBPK modeling

  2023cites this paper
• Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs

  2023cites this paper
• Prediction of pharmacokinetics of an anaplastic lymphoma kinase inhibitor in rat and monkey: application of physiologically based pharmacokinetic model as an alternative tool to minimise animal studies

  2023cites this paper
• In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease

  2023cites this paper
• Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model

  2023cites this paper
• Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets

  2023cites this paper
• Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib

  2022cites this paper
• Assessment of skin toxicity in an in vitro reconstituted human epidermis model using deep learning.

  2022cites this paper
• Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling.

  2022cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs

  2022cites this paper
• Identification of solubility-limited absorption of oral anticancer drugs using PBPK modeling based on rat PK and its relevance to human.

  2020cites this paper
• Applicability of the Øie‐Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase

  2020cites this paper
• A sensitive in vitro performance assay reveals the in vivo drug release mechanisms of long-acting medroxyprogesterone acetate microparticles.

  2020cites this paper
• Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.

  2019cites this paper
• Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth

  2018cites this paper
• Translational Modeling and Simulation for Molecularly Targeted Small Molecule Anticancer Agents: Case Studies of Multiple Tyrosine Kinase Inhibitors, Crizotinib and Lorlatinib

  2018cites this paper
• Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer

  2018cites this paper
• Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide

  2018cites this paper
• Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human

  2017cites this paper
• Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

  2017cites this paper
• Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.

  2017cites this paper
• Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model

  2017cites this paper
• Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity

  2017cites this paper
• Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.

  2016cites this paper
• The Personalization of Drug Therapy for Elderly Patients

  2016cites this paper
• Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin

  2016cites this paper
• Introduction to Kinase Antitargets

  2015cites this paper
• Development of a Physiologically-based Model with a regulatory and excitable cardiovascular system

  2015cites this paper
• Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects

  2015cites this paper
• Crizotinib (Xalkori): The First‐in‐Class ALK/ROS Inhibitor for Non‐small Cell Lung Cancer

  2015cites this paper
• Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human.

  2015cites this paper
• The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

  2015cites this paper
• Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

  2015cites this paper
• Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model

  2015cites this paper
• Interspecies Pharmacokinetics. 1. Allometric Scaling of Pharmacokinetic Parameters (a Review)

  2014cites this paper
• PBPK: Integrating In Vitro and In Silico Data in Physiologically Based Models

  2014cites this paper
• PBPK models for the prediction of in vivo performance of oral dosage forms.

  2014cites this paper
• Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes

  2013influential citation
• Application of Hybrid Approach Based on Empirical and Physiological Concept for Predicting Pharmacokinetics in Humans—Usefulness of Exponent on Prospective Evaluation of Predictability

  2013cites this paper
• Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

  2013cites this paper
• Application of Target-Mediated Drug Disposition Model to Small Molecule Heat Shock Protein 90 Inhibitors

  2013cites this paper
• Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.

  2013cites this paper
• Predicting pharmacokinetic profiles using in silico derived parameters.

  2013cites this paper
• Physiologically Based Pharmacokinetic Models of Tyrosine Kinase Inhibitors: A Systems Pharmacological Approach to Drug Disposition

  2013cites this paper
• Tamoxifen pharmacokinetics and pharmacogenetics in endocrine sensitive breast cancer patients

  2013cites this paper
• Chapter Twenty-Five - Case History: Xalkori™ (Crizotinib), a Potent and Selective Dual Inhibitor of Mesenchymal Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) for Cancer Treatment

  2013cites this paper
• Microsystems manufacturing technologies for pharmaceutical toxicity testing

  2013cites this paper
• DMD049114 343..352

  2013cites this paper
• Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

  2012cites this paper
• Application of PBPK modelling in drug discovery and development at Pfizer

  2012cites this paper
• Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective

  2012cites this paper
• Prediction of drug concentration-time data in humans from animals: a comparison of three methods

  2012cites this paper
• Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling

  2012cites this paper
• Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib

  2012cites this paper
• Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches

  2012cites this paper
• Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of

  2012cites this paper
• Role of ADME Studies in Selecting Drug Candidates: Dependence of ADME Parameters on Physicochemical Properties

  2012cites this paper
• LC-MS in Drug Bioanalysis

  2012cites this paper
• An industrial perspective on contemporary applications of PBPK models in drug discovery and development.

  2012cites this paper
• Renal Cell Carcinoma

  2011cites this paper
• Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

  2011cites this paper
• JPET #188870 1 TITLE: Pharmacokinetic-Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Anti-tumor Efficacy in Human Tumor Xenograft Mouse Models AUTHORS:

  2011cites this paper
• Exploitation of Aberrant Signalling Pathways as Useful Targets for Renal Clear Cell Carcinoma Therapy

  2011cites this paper
• Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist

  2011cites this paper
• Preclinical and Clinical Pharmacokinetics of PF-02413873, a Nonsteroidal Progesterone Receptor Antagonist

  2011cites this paper
• A critique of the EC's expert (draft) reports on the status of alternatives for cosmetics testing to meet the 2013 deadline.

  2011cites this paper